Securing the indication of the world's first long-acting growth hormone ISS globally, is there a solution to the situation of both revenue and net profit decline at Changchun High-tech Industries? | Announcement for quick reading

①On the 5th, changchun high-tech industries announced that its long-acting growth hormone has been approved for ISS indication. In August of this year, this variety was also approved for the growth disorder in girls with gonadal dysgenesis (Turner syndrome); ②In the first three quarters of this year, changchun high-tech industries' performance and profitability both declined. Whether the main products that have been on the market for 10 years can have new sales volume is widely watched.

cls.cnNov 5 09:31 ET

Sales of the herpes zoster vaccine declined, dragging down Bacillus's third-quarter revenue by over 40%.

① Due to the reduction in sales of attenuated live herpes zoster vaccine, Baike Biotechnology achieved a year-on-year decrease in revenue of 40.37% in the third quarter, with a year-on-year decrease in net income attributable to the parent company of 51.41%; ② Currently, in addition to GSK's herpes zoster vaccine competing with Baike Biotechnology in the domestic market, there are over 10 companies developing similar products, Baike Biotechnology faces multiple potential competitors.

cls.cnOct 25 07:16 ET

IVD sector growth cannot hide the decline in performance. Q0.03 million Tai Biological net profit plummeted more than 90%. | Interpretations

①Affected by market adjustments, government centralized procurement, etc., beijing wantai biological pharmacy enterprise's biological vaccine sector continues to drag down the company's performance. ② The company's diagnostic sector business has grown, and the chemiluminescence product line maintained rapid double-digit growth compared to the same period last year. ③ With factors such as increased investment in industrialization of the nine-valent HPV vaccine, beijing wantai biological pharmacy enterprise's revenue and net profit attributable to the parent company decreased significantly in the first three quarters.

cls.cnOct 24 10:08 ET

The performance decline continues, tonghua dongbao pharmaceutical's Q3 sales expenses exceed 0.3 billion yuan|interpretations

Due to factors such as a significant decrease in revenue and the termination of research and development pipelines, tonghua dongbao pharmaceutical handed in a loss-making third-quarter report. From the perspective of Q3 performance, the company's revenue shows a certain recovery trend, but the escalating sales expenses quarter by quarter have resulted in a situation of "increased revenue without increased profits".

cls.cnOct 24 09:02 ET

Overseas income increased, the effects of a new round of follow-up procurement strategies are showing. Net income of gan & lee pharmaceuticals in the first three quarters nearly doubled. | Interpretations of financial reports

1. In the first three quarters of this year, gan & lee pharmaceuticals' domestic and international revenues both increased year-on-year. 2. The company won the insulin special procurement bid, and the revenue growth effect brought by the rise in bid product prices began to show in Q3. 3. The company is attempting to sell insulin products overseas, and the increase in milestone revenue is also one of the factors contributing to the company's performance growth.

cls.cnOct 22 10:08 ET

Unconventional business continues to drag down Yiqiao Shenzhou's performance. The cumulative stock buyback has exceeded 0.4 billion yuan | Interpretations

①Affected by factors such as the decline in unconventional business income and fluctuations in cash management income, Yiqiao Shenzhou's third quarter revenue and net income attributable to the parent both declined; ②Increased investment in CRO services and conventional reagent business caused the company's cost of goods sold to increase by more than 30% year-on-year; ③Yiqiao Shenzhou has repurchased the company's shares twice this year, totaling more than 0.4 billion yuan.

cls.cnOct 22 08:28 ET